Tacrolimus Online



How and where to order Protopic (Tacrolimus) ointment topical 0.03% and 0.1% in tubes 10 g or Prograf (Tacrolimus) 0.25 mg, 0.5 mg, 1 mg, 2 mg capsules or tablets online on the Inflammatory Skin Disease Institute (ISDI) website:

Shop:CHEAP MEDS FOR SALE
Stores:PHARMA DOCTOR
Prices:
  • from $25.00 per tube
  • from $1.45 per pill
  • Discount:5% coupon: 5OFF
    Forms:
  • topical ointment 0.03% and 0.1% 10 g tubes
  • 0.25 mg, 0.5 mg, 1 mg, 2 mg capsules and tablets
  • Quantity:
  • 1-5 tubes
  • 10-180 pills
  • Type:
  • Tacrolimus brand
  • Protopic generic
  • Prograf generic
  • Payment:Visa, Mastercard, AmEx, eCheck, Bitcoin
    Delivery:Regular and express mail service
    Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


    Tacrolimus (trade names include Protopic, Prograf, Advagraf, Astagraf XL, Crolim, Envarsus XR, Hecoria, Tacrolimus Accord, PanGraf, Rocimus, Tacroderm, Tacrograf, Tacrolimus Sandoz, Tacrotor, Tacroz, Talimus, Topgraf, Vingraf) is a dermatological and immunosuppressant medication from agents for dermatitis and calcineurin inhibitors pharmacological groups. This medicine is used as a topical ointment and systemic immunosuppressive drug for the treatment of atopic dermatitis, eczema, psoriasis, to reduce the risk of organ rejection after organ transplantation, for severe refractory uveitis after a bone marrow transplant, exacerbations of minimal change disease, Kimura's disease, vitiligo. It is indicated in veterinary medicine for the therapy dry eye syndrome in cats and dogs. Tacrolimus is also in research studies to treat ulcerative colitis, and to reduce the risk of serious infections in lupus nephritis. This drug works by inhibiting calcineurin, which is involved in the production of interleukin-2, a molecule that promotes the development and proliferation of T cells, as part of the body's learned (or adaptive) immune response.


    Protopic, Prograf (Tacrolimus) ointment and capsules


    Related medications:

  • Abrocitinib (Cibinqo)
  • Alitretinoin (Panretin)
  • Azathioprine (Imuran)
  • Bemzocaine (Mucopain)
  • Cromoglicic Acid (Intal)
  • Cyclopentolate (Cyclogyl)
  • Cyclosporine (Neoral)
  • Dupilumab (Dupixent)
  • Eucrisa (Crisaborole)
  • Lidocaine, Prilocaine (Emla)
  • Mycophenolate Mofetil (CellCept)
  • Pimecrolimus (Elidel)
  • Povidone-Iodine (Betadine)
  • Tralokinumab (Adtralza, Adbry)
  • Tranexamic Acid (Cyklokapron)
  • Voclosporin (Lupkynis)
  • Xylocaine (Lidocaine)


    Pharmacological and medical categories:

  • Anti cancer drugs
  • Dermatologic therapy
  • Immunosuppressive drugs
  • Skin care products
  • Surgery medicines
  • T-cell-mediated diseases treatment
  • Topical preparations
  • Transplant medications
  • Veterinary, pet meds


    ATC codes:

  • D - Dermatologicals
  • D11 - Other dermatological preparations
  • D11A - Other dermatological preparations
  • D11AH - Agents for dermatitis, excluding corticosteroids
  • D11AH01 - Tacrolimus

  • L - Antineoplastic and immunomodulating agents
  • L04 - Immunosuppressants
  • L04A - Immunosuppressants
  • L04AD - Calcineurin inhibitors
  • L04AD02 - Tacrolimus


    ICD-10 codes:

  • Other benign neoplasms of connective and other soft tissue - D21
  • Benign neoplasm of connective and other soft tissue, unspecified - D21.9
  • Iridocyclitis - H20
  • Ulcerative colitis - K51
  • Dermatitis and eczema - L20-L30
  • Atopic dermatitis - L20
  • Psoriasis - L40
  • Vitiligo - L80
  • Systemic lupus erythematosus (SLE) - M32
  • Glomerular disease in systemic lupus erythematosus - M32.14
  • Nephrotic syndrome - N04
  • Nephrotic syndrome with minor glomerular abnormality - N04.0
  • Unspecified nephritic syndrome - N05
  • Unspecified nephritic syndrome with minor glomerular abnormality - N05.0
  • Transplanted organ and tissue status - Z94
  • Bone marrow transplant status - Z94.81


    Indications and usage for Protopic:

    Protopic (Tacrolimus) ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable.


    Contraindications:

    Protopic ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.


    Dosage and administration:

    Adult

    Protopic (Tacrolimus) ointment 0.03% and 0.1%:

  • Apply a thin layer of Protopic ointment to the affected skin twice daily. The minimum amount should be rubbed in gently and completely to control signs and symptoms of atopic dermatitis. Stop using when signs and symptoms of atopic dermatitis resolve.
  • If signs and symptoms (e.g. itch, rash, and redness) do not improve within 6 weeks, patients should be re-examined by their healthcare provider to confirm the diagnosis of atopic dermatitis.
  • Continuous long-term use of topical calcineurin inhibitors, including Protopic ointment should be avoided, and application should be limited to areas of involvement with atopic dermatitis.

    The safety of Tacrolimus (Protopic) under occlusion, which may promote systemic exposure, has not been evaluated. This medication should not be used with occlusive dressings.

    Pediatric: for children 2-15 years

    Protopic (Tacrolimus) ointment 0.03%:

  • Apply a thin layer of Protopic ointment, 0.03% to the affected skin twice daily. The minimum amount should be rubbed in gently and completely to control signs and symptoms of atopic dermatitis. Stop using when signs and symptoms of atopic dermatitis resolve.
  • If signs and symptoms (e.g. itch, rash, and redness) do not improve within 6 weeks, patients should be re-examined by their healthcare provider to confirm the diagnosis of atopic dermatitis.
  • Continuous long-term use of topical calcineurin inhibitors, including Protopic should be avoided, and application should be limited to areas of involvement with atopic dermatitis.

    The safety of this drug under occlusion, which may promote systemic exposure, has not been evaluated. Tacrolimus ointment should not be used with occlusive dressings.


    Dosage forms and strengths:

    Protopic (Tacrolimus) ointment for topical use 0.03% and 0.1% in tubes 10 g, 30 g, 60 g, 100 g.


    Overdosage:

    Tacrolimus (Protopic) ointment is not for oral use. Oral ingestion of this medicine may lead to adverse effects associated with systemic administration of tacrolimus. If oral ingestion occurs, medical advice should be sought.


    Warnings and precautions:

    Long-term safety of topical calcineurin inhibitors has not been established.

    Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Protopic (Tacrolimus) topica ointment.

    Continuous long-term use of topical calcineurin inhibitors, including Protopic, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis.

    Tacrolimus ointment is not indicated for use in children less than 2 years of age. Only 0.03% Protopic ointment is indicated for use in children 2-15 years of age.


    Adverse reactions, side effects:

    The most common adverse reactions of tacrolimus topical ointment are skin burning, pruritus, flu-like symptoms, allergic reaction, skin erythema, headache, skin infectiona, fever, accidental injury, otitis media, nausea, dry skin.

    To report suspected adverse reactions of Protopic (Tacrolimus) ointment, contact LEO pharmaceutical company or your local FDA.


    Use in specific populations:

    Pregnancy

    There are no adequate and well-controlled studies of topically administered tacrolimus in pregnant women. The experience with Protopic ointment when used by pregnant women is too limited to permit assessment of the safety of its use during pregnancy.

    Nursing mothers

    Although systemic absorption of tacrolimus following topical applications of Protopic topical ointment is minimal relative to systemic administration, it is known that tacrolimus is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from tacrolimus, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    Pediatric use

    Only Protopic (Tacrolimus) ointment 0.03% is recommended for use as a second-line therapy for short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised children 2 to 15 years of age who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable.

    Geriatric use

    Four hundred and four (404) patients >= 65 years old received Tacrolimus (Protopic) ointment in phase 3 studies. The adverse event profile for these patients was consistent with that for other adult patients.


    Pregnancy categories:

  • B2 - Australia
  • B - United States (No evidence of risk in humans)


    Salts and other forms:

  • Tacrolimus Base
  • Tacrolimus Anhydrous
  • Tacrolimus Hydrate
  • Tacrolimus Monohydrate


    Synonyms, international and chemical names:

  • Tacrolimo
  • Tacrolimws
  • Takrolimus
  • Takrolimusz
  • Takrolimuusi


    Brands, generics, trade names:

  • Advagraf - Astellas Pharma
  • Astagraf XL - Astellas Pharma
  • Crolim - Ranbaxy
  • Cromidin - Alpes Chemie, Royal Pharma
  • Envarsus XR - Veloxis Pharmaceuticals, Chiesi
  • Hecoria - Novartis
  • PanGraf - Panacea Biotec
  • Proalid - Darier Laboratorios Dermatologicos
  • Prograf - Astellas Pharma
  • Protopic - LEO Pharma
  • Rocimus - The Madras Pharmaceuticals, Mega Lifesciences
  • Tacroderm - Abbott
  • Tacrograf - Biocon
  • Tacrolimus - Accord Healthcare, Mylan, Sandoz
  • Tacromus - Zydus Cadila
  • Tacro-Tic - Cinetic Laboratories Argentina
  • Tacrotor - Torrent Pharmaceuticals
  • Tacroz - Glenmark Pharmaceuticals
  • Tacroz Forte - Glenmark Pharmaceuticals
  • Talimus - Ajanta Pharma
  • T-Inmun - Recalcine Laboratorios
  • Topgraf - GlaxoSmithKline
  • Traderma - Serral
  • Vingraf - Emcure Pharmaceuticals, Macropharma Corporation


    Here is a list of popular medications containing tacrolimus as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Astagraf XL
  • Capsules, Extended Release; Oral; Tacrolimus 0.5 mg
  • Capsules, Extended Release; Oral; Tacrolimus 1 mg
  • Capsules, Extended Release; Oral; Tacrolimus 5 mg
  • Astellas Pharma
  • Prograf
  • Capsules; Oral; Tacrolimus 0.25 mg
  • Capsules; Oral; Tacrolimus 0.5 mg
  • Capsules; Oral; Tacrolimus 1 mg
  • Capsules; Oral; Tacrolimus 2 mg
  • Capsules; Oral; Tacrolimus 5 mg
  • Astellas Pharma
  • Adcock Ingram
  • DKSH
  • Firma Chun Cheong
  • Fujisawa
  • Gador
  • Janssen
  • Pharma Investi de Chile
  • Pro-Pharma
  • Teva
  • Vianex
  • Zuellig Pharma
  • Protopic
  • Ointment; Topical; Tacrolimus 0.03%
  • Ointment; Topical; Tacrolimus 0.1%
  • LEO Pharma
  • Astellas Pharma
  • DKSH
  • Firma Chun Cheong
  • Fujisawa
  • Gador
  • Janssen
  • Roche
  • Teva
  • Vianex
  • Zuellig Pharma



  • References:

  • Tacrolimus main article on Wikipedia: https://en.wikipedia.org/wiki/Tacrolimus
  • Tacrolimus compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Tacrolimus
  • Prograf (Tacrolimus) on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Prograf
  • Tacrolimus medicine on DrugBank: https://go.drugbank.com/drugs/DB00864
  • Tacrolimus Hydrate on DrugBank: https://go.drugbank.com/salts/DBSALT000167
  • Tacrolimus FAQ on MedlinePlus (revised 09/15/2021): https://medlineplus.gov/druginfo/meds/a601117.html
  • Tacrolimus Topical on MedlinePlus (revised 02/15/2016): https://medlineplus.gov/druginfo/meds/a602020.html
  • Tacrolimus Injection on MedlinePlus (revised 02/15/2018): https://medlineplus.gov/druginfo/meds/a608037.html
  • Prograf (Tacrolimus) capsules, injection solution, granules for suspension drug label on DailyMed (revised July 21, 2021): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Protopic (Tacrolimus) ointment drug label on DailyMed (revised May 24, 2010): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Mylan Tacrolimus capsules drug label on DailyMed (revised July 27, 2021): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Tacrolimus containing drugs on Drugs-About.com: https://drugs-about.com/ing/tacrolimus.html
  • Tacrolimus for sale on Pharma Doctor (revised January 2022): https://pharma-doctor.com/tacrolimus.html
  • Prograf (Tacrolimus) capsules for oral use, injection for intravenous use, granules for oral suspension official prescribing and patient information from the U.S. FDA (revised 05/2018): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Prograf (Tacrolimus) capsules, injections, granules official website by Astellas Pharma Inc.: https://www.prograf.com/
  • Protopic (Tacrolimus) ointment 0.03% and 0.1% official prescribing information and medication guide from the U.S. FDA (revised 11/2011): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Protopic (Tacrolimus) ointment prescribing information and medication guide from LEO Pharma (revised 02/2019): https://www.leo-pharma.us/Files/Billeder/...
  • Astagraf XL (Tacrolimus) extended release capsules official website by Astellas Pharma Inc.: https://www.astagrafxl.com/
  • Prograf (Tacrolimus) 0.5 mg, 1 mg, 5 mg hard capsules package information leaflet from Medicines.org.uk (revised October 2021): https://www.medicines.org.uk/emc/files/pil.6720.pdf
  • Protopic (Tacrolimus Monohydrate) 0.03% ointment package information leaflet from Medicines.org.uk (revised June 2021): https://www.medicines.org.uk/emc/files/pil.1612.pdf
  • Protopic (Tacrolimus Monohydrate) 0.1% ointment package information leaflet from Medicines.org.uk (revised June 2021): https://www.medicines.org.uk/emc/files/pil.1608.pdf

    Revised: January 2022



    Home | About ISDI | Inflammatory Skin Diseases | Patient Information | News/Events | Newsletter | Contact Us

    Copyright © 2001 - 2022 Inflammatory Skin Disease Institute (ISDI), Inc. All Rights Reserved.